GLP-1 receptor agonist
Semaglutide
A prescription peptide medicine with established uses, product-specific labels, and an important divide between approved and unapproved versions.
Also known as Ozempic · Wegovy · Wegovy HD · Rybelsus · GLP-1 analogue
01 · Evidence profile
One molecule, four evidence questions
Large controlled programs support specific approved indications.
Pharmacology and exposure are extensively characterized for approved products.
Approved labels describe established risks, monitoring, and contraindications.
High for an authentic approved product; not transferable to every compounded version.
02 · Identity
What it is
Semaglutide is the active ingredient in several prescription medicines. Approval, indication, formulation, route, and safety information belong to the specific drug product and its current FDA-approved label.
03 · Product identity
The molecule is not the finished product.
Ozempic, Wegovy, and Rybelsus are distinct approved products. Evidence, formulation, route, indication, and labeling belong to the exact product.
Ozempic
May 2026- Formulation
- Injection
- Route
- Subcutaneous
- Indication scope
- Adults with type 2 diabetes for labeled glycemic, cardiovascular, and chronic-kidney-disease risk-reduction uses.
Rybelsus
October 2025- Formulation
- Tablet
- Route
- Oral
- Indication scope
- Adults with type 2 diabetes for the uses and product strengths defined in the current label; not a weight-management approval.
Wegovy
March 2026- Formulation
- Injection and tablet formulations
- Route
- Subcutaneous or oral, depending on formulation
- Indication scope
- Product- and formulation-specific chronic weight management and labeled risk-reduction uses; populations differ by indication.
Wegovy HD
March 2026- Formulation
- 7.2 mg injection strength
- Route
- Subcutaneous
- Indication scope
- The higher-dose Wegovy injection option for the adult population and weight-management use defined in the current label.
- Ozempic
- Wegovy
- Wegovy HD
- Rybelsus
- Type 2 diabetes for labeled populations
- Chronic weight management for labeled populations
- Cardiovascular and kidney-risk indications described in current labels
04 · Evidence snapshot
What the evidence can and cannot say
FDA-reviewed products containing semaglutide have approved indications and official prescribing information. Those labels are the primary source for who a product is for, contraindications, warnings, adverse reactions, and administration.
Evidence for an approved product cannot automatically be transferred to an unapproved, compounded, counterfeit, or research-labeled product. Similar naming does not establish equivalent quality, safety, or effectiveness.
05 · Claim check
Three claims under the lens
“Semaglutide is FDA-approved.”
Some drug products containing semaglutide are FDA-approved for specific uses. The product, formulation, and indication matter.
- Evidence basis
- Regulatory or product record
- Scope
- Specific FDA-approved semaglutide products, formulations, populations, and indications in their current labels.
“Compounded semaglutide is the same as an approved product.”
FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.
- Evidence basis
- Regulatory or product record
- Scope
- Compounded or otherwise unapproved semaglutide products compared with FDA-approved products.
“A result in one population proves the same benefit for everyone.”
Trial population, endpoint, formulation, dose, duration, and indication define what a study can support.
- Evidence basis
- Randomized human outcomes
- Scope
- The populations, formulations, endpoints, and durations described in the cited approved-product record.
06 · Safety boundary
Before this becomes personal
This guide does not recommend a product, decide eligibility, or provide dosing. Medication decisions belong with a licensed clinician using the current label and the patient’s medical history.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed 2026-07-23. This status is not personal clearance to compete.07 · Sources
Check the primary record
08 · Provenance
Review history
Expanded product, claim, and source provenance fields.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.